Cantourage Group SE Sees Growth in Cannabis Market Amid U.S. Rescheduling

Cantourage Group SE acknowledges the potential global impact of recent U.S. cannabis rescheduling discussions. The proposed reclassification of cannabis to Schedule III under the Controlled Substances Act could enhance U.S. market profitability. This change may ease tax burdens under Section 280E, reflecting broader acceptance of cannabis as an economic and medical product. Cantourage views these U.S. developments as indicative of a growing global cannabis market.

Cantourage anticipates that improved financial conditions for U.S. firms may lead to increased international investments and partnerships. The company aims to leverage its strong European presence to engage with this evolving market landscape. Philip Schetter, CEO, emphasizes Europe's emerging high-quality market structures as promising long-term growth avenues.

As part of its strategy, Cantourage will closely follow international regulatory changes to align its growth plans with new opportunities. The company is positioned to capitalize on strategic international partnerships, bolstered by its platform facilitating European market entry for global cannabis producers.